Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Awakn Life Sciences Corp (OP: AWKNF )

0.0888 UNCHANGED
Streaming Delayed Price Updated: 10:29 AM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Awakn Life Sciences Corp

< Previous 1 2 3 4 5 Next >
Can Ketamine Treat Alcohol Addiction? How Therapy Actually Functions?
(Part two of a four-part series) 
Via Benzinga
Can Ketamine Treat Alcohol Addiction? Clinics & Hospitals In Europe And North America Are Already Doing It
(Part one of a four-part series) The use of psychedelic-assisted psychotherapy for the treatment of mental health conditions has become a hot topic, with a growing general sense of acceptance, public... 
Via Benzinga
Awakn And Catalent's Partnership Could Provide Hope For People Suffering From Addiction
Since 2020, Awakn Life Sciences Corp. (OTCQB: AWKNF) reports that it has been researching, developing and commercializing therapeu 
Via Benzinga
Psychedelic Stocks Continue To Plummet: -16% This Week; -33% MTD; Now -57% YTD
Look at how the only psychedelic stocks with market caps larger than $50M gave performed this last week. 
Via Talk Markets
8 Largest Psychedelic Stocks Continued Their Decline Last Week
The 8 stocks in the munKNEE Psychedelic Compounds-Based Drug Stocks Index were collectively down 10% in the past week. We also take a look at some therapy-clinic stocks. 
Via Talk Markets
Awakn Shares Its Q2 2022 Results, Showing Consistent Growth On Its Second Full Financial Year
Biotech firm leading the Alcohol Use Disorder (AUD) treatment Awakn Life Sciences Corp. (OTCQB: AWKNF) has announced its financial outcomes and business highlights for the three months ended July 31,... 
Via Benzinga
Psychedelics Companies Are Teaming Up To Offer Access Veterans
Two psychedelics companies have announced they’ll be collaborating to offer ketamine infusions in the US and psilocybin clinical retreats internationally with a special focus on  access needs for... 
Via Benzinga
Psychedelics Companies Seek Innovative Methods To Deliver Assisted Therapies, This One Stands Out
As competence grows, biopharmaceuticals are searching for ways to present their specific psychedelic substance-assisted therapies in a way that might differentiate them from their competitors while... 
Via Benzinga
Battling With Booze? Here's A Deeper Look At Ketamine for Alcohol Use Disorder
This article by Elisabetta Fato was originally published on Microdose and appears here with permission. In the last decades, there has been a growing interest in psychedelics for the treatment of mood... 
Via Benzinga
Most, But Not All, Psychedelics Companies Have Sufficient Liquidity
The Chart represents the liquidity positions of the 21 Psychedelic sector companies in the Viridian Value Tracker database. 
Via Benzinga
World Class Leaders In Psychedelics Form Benzinga's Psychedelic Advisory Council—Get To Know Them
The Benzinga Psychedelics Advisory Council was introduced in March of 2022 with the sustained goal of better informing investors and general audience about the psychedelics financial and business... 
Via Benzinga
There Could Be More Hope For Alcohol Addicts As This Company Enters U.S. Addiction Treatment And Relapse Prevention Market
For people suffering from any type of addiction, getting the best medical care can make a significant difference in their journey to recovery. In the case of alcohol abuse, for example, the talk about... 
Via Benzinga
Awakn's Second Licensing Partnership Agreement In A Week, This Time In Canada: Ketamine For Pain Comorbidities
Psychedelics therapeutics biotech company Awakn Life Sciences Corp. (OTCQB: AWKNF) has signed what constitutes its first licensing partnership deal in Canada. 
Via Benzinga
Awakn Enters U.S. Addiction Treatment & Relapse Prevention Market With Ketamine Therapy For Alcohol Use Disorder
Awakn Life Sciences Corp. (OTCQB: AWKNF), the biotech company focused on addiction treatments, has signed a licensing partnership agreement with US ketamine therapy clinics owner Revitalist Lifestyle... 
Via Benzinga
Phase 3 Trial On Ketamine Therapy Gets Almost $2M From UK State Funding
Biotech psychedelics company Awakn Life Sciences Corp. (OTCQB: AWKNF) has been granted funding for 66% of the costs from its phase 3 clinical trial  on  
Via Benzinga
Awakn Life Sciences Receives Funding From UK Government To Identify Most Efficient Go-To-Market Pathway For Proprietary Ketamine-Assisted Therapy
Awakn Life Sciences Corp. (OTCQB: AWKNF) reported it secured funding from Innovate UK to identify the quickest and most cost-effective route to market in both the U.K. and the U.S. 
Via Benzinga
Awakn Life Sciences: Business And Corporate Update For Psychedelics Biotech
Biotech psychedelics company Awakn Life Sciences Corp. (OTCQB: AWKNF) has just published its business and corporate updates. 
Via Benzinga
Michael Pollan's 'How To Change Your Mind' Now On Netflix, Here Are Reactions From Experts
Michael Pollan's 2018 book “How To Change Your Mind: What the science of psychedelics teaches us about consciousness, dying, addiction, depression, and transcendence” is available on Netflix (NASDAQ:... 
Via Benzinga
UK To Fund Development Of Awakn's Ketamine-Assisted Therapy Program For Alcohol Use Disorder In US And UK
Biotech therapeutics company Awakn Life Sciences Corp. 
Via Benzinga
Michael Pollan's 'How To Change Your Mind' Coming Soon To Netflix: Documentary Based On Psychedelics Best Seller
The freshest news traversing many of the major institutions, researchers' and activists’ accounts on Twitter is the recent release of a docu-series based on writer Michael Pollan’s 2018 book “How To... 
Via Benzinga
These 18 Clinical Trials Could Shape The Future Of The Psychedelics Industry
In the nascent industry of medical psychedelics, drug development is the name of the game. This subset of biotech, poised to become a $100 billion industry according to Canaccord Genuity, bases its... 
Via Benzinga
Psyched: Medical Psychedelics In Davos, Canadian Sen Does Psychedelics, Ei.Ventures & Mycotopia To Merge Into $383M Company
Medical Psychedelics have made it into Davos, just in time for the World Economic Forum. 
Via Benzinga
Awakn Life Sciences Reports Completing World's First Ketamine Study For A Range Of Behavioral Addictions
Photo by Tranava University on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Could Ketamine be a... 
Via Benzinga
Awakn's Study On Psychedelics For Treating Addiction Shows Promise, Will Undertake Broader Research
Awakn Life Sciences (OTCQB: AWKNF) has announced the successful completion of the first ketamine study for a varied set of behavioral addictions. 
Via Benzinga
Wake-Up Call: This Biotech Company Is Using Psychedelics To Treat Addiction
This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. 
Via Benzinga
Core One Labs Begins Trading On OTCQB
Under the CLABF symbol, psychedelics-oriented company Core One Labs (OTCQB: CLABF) started trading on the OTCQB Venture ... 
Via Benzinga
Psyched: Atai, MindMed, Enveric and Mydecine Release 2021 Earnings, Bienstar Expands To Brazil & More!
It’s earnings week in the psychedelics space, opening a new window into the financial situations of many companies in the sector. 
Via Benzinga
Stifel Initiates Coverage On Awakn Life Sciences With A Speculative Buy, $8 Target Price Target
Awakn Life Sciences (OTC: AWKNF) is in the news after a respected analyst has upgraded the stock.  Awakn is a publicly traded company which trades on the over-the-counter market with the symbol of  
Via Benzinga
This Biotech Company Is Landing Ketamine-Assisted Therapy In England's Capital
This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. As it pushes ahead with expansion into the United States,... 
Via Benzinga
Awakn Life Sciences Seeks To Treat Addictions: Gambling, Binge Eating And Compulsive Sexual Behavior
Awakn Life Sciences (OTC: AWKNF) is not only going after alcoholism but also binge eating disorder, compulsive sexual behavior and even Internet gaming disorder. 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.